Oncology Times (@oncologytimes) 's Twitter Profile
Oncology Times

@oncologytimes

Reporting essential clinical news w/ independent analysis for cancer care professionals to optimize patient care & outcomes; oncology/hematology

ID: 19495715

linkhttp://oncology-times.com calendar_today25-01-2009 17:22:19

29,29K Tweet

53,53K Followers

8,8K Following

Oncology Times (@oncologytimes) 's Twitter Profile Photo
Oncology Times
@oncologytimes

12 days ago

The #FDA approved dostarlimab-gxly with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for adult patients with primary advanced or recurrent #EndometrialCancer. ow.ly/VQiR50TgVnG

The #FDA approved dostarlimab-gxly with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for adult patients with primary advanced or recurrent #EndometrialCancer. ow.ly/VQiR50TgVnG